Erasca (ERAS) Net Income towards Common Stockholders (2020 - 2026)
Erasca (ERAS) reported Net Income towards Common Stockholders of -$183.5 million for Q1 2026, down 492.46% on a YoY basis from $46.7 million in Q1 2025, and down 531.8% quarter-over-quarter from -$29.0 million in Q4 2025.
Erasca (ERAS) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Erasca has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$183.5 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 492.46% year-over-year to -$183.5 million; the trailing twelve-month figure through Mar 2026 stood at -$277.0 million (down 77.57% YoY), and the FY2025 full-year result was -$124.5 million, up 22.95% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$183.5 million, down from -$29.0 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$29.0 million in Q4 2025, with the low at -$183.5 million in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged -$49.2 million across 5 years, with a median of -$33.2 million in 2023.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders jumped 78.04% — and 2026, when it plunged 492.46%.
- Erasca's Net Income towards Common Stockholders stood at -$135.2 million in 2022, then jumped by 78.04% to -$29.7 million in 2023, then dropped by 2.45% to -$30.4 million in 2024, then climbed by 4.57% to -$29.0 million in 2025, then slumped by 531.8% to -$183.5 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$183.5 million (Q1 2026), -$29.0 million (Q4 2025), and -$30.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Erasca | 4.28 Bn | 4.03 Bn | - | -183.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -183.46 Mn |
| Dec 31, 2025 | -29.04 Mn |
| Sep 30, 2025 | -30.58 Mn |
| Jun 30, 2025 | -33.88 Mn |
| Mar 31, 2025 | -30.97 Mn |
| Dec 31, 2024 | -30.43 Mn |
| Sep 30, 2024 | -31.37 Mn |
| Jun 30, 2024 | -63.20 Mn |
| Mar 31, 2024 | -35.02 Mn |
| Dec 31, 2023 | -29.70 Mn |
| Sep 30, 2023 | -30.36 Mn |
| Jun 30, 2023 | -31.78 Mn |
| Mar 31, 2023 | -33.20 Mn |
| Dec 31, 2022 | -135.25 Mn |
| Sep 30, 2022 | -35.49 Mn |
| Jun 30, 2022 | -35.61 Mn |
| Mar 31, 2022 | -36.46 Mn |
| Dec 31, 2021 | -30.97 Mn |
| Sep 30, 2021 | -46.07 Mn |
| Jun 30, 2021 | -28.21 Mn |